Dr. Shannon received his Ph.D. in organic chemistry in 1978 from Massachusetts Institute of Technology. After a two year NIH postdoctoral at the University of California and a period as a start up scientist in a biotechnology company he became a Group Leader, New Product Research, at Dupont in a program developing monoclonal antibodies for the treatment of autoimmune diseases. In 1990 he moved to the San Francisco area and became Manager, Pharmaceutical Project Development at Triton Biosciences where he was responsible for the project management of pharmaceutical drug development from the late research stage through Phase III clinical trials, and in the preparation of FDA submissions. After the development and approval of two new drugs, Triton Biosciences was subsequently purchased by Berlex Laboratories. In 1994 he accepted the position of Director, Pharmaceutical Project Development at Matrix Pharmaceutical, Inc. where he founded and headed corporate project management until 1998. In 1998, he joined Ilex Oncology, in San Antonio, TX. He was head of the project management department and the project manager for the successful development of Campath for treatment of CLL. Following FDA approval of Campath, he took on additional responsibilities for the management of the departments covering CMC (manufacturing, QC, formulation), Pharmacology, Toxicology, and Clinical Trial Material management. In 2003, he joined OSI to assume the position as Sr. Director, Project Management, OSI Pharmaceuticals, Inc., a department of 6 professionals who are responsible for oncology IND candidates through product launch.